Relay Therapeutics Advances Zovegalisib Triplet to Phase 3 for Frontline Breast Cancer with Promising Clinical Data

summarizeSummary

Relay Therapeutics reported positive Phase 1/2 clinical data for its zovegalisib triplet combination and announced plans to advance it into a Phase 3 trial for frontline metastatic breast cancer, supported by a drug supply agreement with Pfizer.

check_boxKey Events

• Positive Phase 1/2 Clinical Data for Zovegalisib Triplet

  The zovegalisib, atirmociclib, and fulvestrant triplet achieved a 44% objective response rate (ORR) in heavily pre-treated (median third-line) PI3Kα-mutated, HR+/HER2- metastatic breast cancer patients, with a manageable 40% Grade 3+ treatment-related adverse event (TRAE) rate.

• Advancement to Frontline Phase 3 Development

  Based on the promising data, Relay Therapeutics plans to initiate a randomized Phase 3 trial evaluating the zovegalisib plus atirmociclib and aromatase inhibitor (AI) triplet in frontline endocrine-sensitive patients, targeting a significant market.

• Pfizer Collaboration for Drug Supply

  Pfizer, Inc. has agreed to supply atirmociclib for the experimental arm and palbociclib for the control arm of the planned Phase 3 trial, with Relay Therapeutics sponsoring and funding the study.

• Strategic Pipeline Progress

  This clinical milestone for zovegalisib, which previously received Breakthrough Therapy Designation, reinforces the company's pipeline strength and follows a recent 10-K filing indicating an extended cash runway into 2029.

auto_awesomeAnalysis

Relay Therapeutics announced compelling Phase 1/2 clinical data for its zovegalisib plus atirmociclib triplet combination in heavily pre-treated metastatic breast cancer patients. The 44% objective response rate (ORR) in these median third-line patients, coupled with a manageable safety profile (40% Grade 3+ TRAEs), is a strong signal, approaching the ORR of current standard of care doublets in frontline (1L) patients. This positive data supports the company's decision to advance the triplet into a Phase 3 trial for 1L PI3Kα-mutated, HR+/HER2- metastatic breast cancer, a substantial market opportunity. The collaboration with Pfizer for drug supply further de-risks the Phase 3 execution. This development significantly strengthens the investment thesis for Relay Therapeutics' lead asset, building on the previously announced Breakthrough Therapy Designation and extended cash runway into 2029.